Edition:
United Kingdom

Biotest AG (BIOG_p.DE)

BIOG_p.DE on Xetra

23.25EUR
10 Dec 2018
Change (% chg)

-- (--)
Prev Close
€23.25
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
9,098
52-wk High
€27.70
52-wk Low
€18.66

Latest Key Developments (Source: Significant Developments)

Biotest Takes Next Step In Developing New Haemophilia Therapeutic To Target Patient Needs
Tuesday, 4 Dec 2018 

Dec 4 (Reuters) - BIOTEST AG ::TAKES NEXT STEP IN DEVELOPING A NEW HAEMOPHILIA THERAPEUTIC TO TARGET PATIENT NEEDS.EXERCISES ITS OPTION AND RECEIVES EXCLUSIVE RIGHTS FOR HAEMOPHILIA ON USE OF AFFIBODY'S ALBUMOD(TM) TECHNOLOGY DESIGNED TO PROLONG HALF LIFE OF BIOPHARMACEUTICALS.PRECLINICAL RESULTS SUGGEST A HIGH PROBABILITY OF SUCCESS FOR IMPROVING PROPERTIES OF INNOVATIVE NEW BIOPHARMACEUTICALS IN HAEMOPHILIA.  Full Article

Biotest Acquires Ninth Plasma Collection Center In Germany
Thursday, 15 Nov 2018 

Nov 15 (Reuters) - Biotest AG ::DGAP-NEWS: BIOTEST AG: BIOTEST AG ACQUIRES NINTH PLASMA COLLECTION CENTER IN GERMANY.100% SUBSIDIARY PLASMA SERVICE EUROPE TAKES OVER PLASMA CENTRE IN HANOVER.CLOSING OF TRANSACTION IS EXPECTED IN Q1 2019..  Full Article

Biotest Posts H1 Profit After Tax At EUR 185.7 Mln
Tuesday, 14 Aug 2018 

Aug 14 (Reuters) - Biotest AG ::DGAP-NEWS: BIOTEST AG: BIOTEST INCREASES REVENUES TO EUR 200.7 MILLION IN THE FIRST HALF OF 2018.H1 EBIT 600,000 EUR.H1 PROFIT AFTER TAX 185.7 MILLION EUR VERSUS -17.8 MILLION EUR LOSS YEAR AGO.H1 REVENUE 200.7 MILLION EUR.SEES FY 2018 SALES OF CONTINUING OPERATIONS TO INCREASE BY A MID-SINGLE-DIGIT PERCENTAGE.ANTICIPATES FY EBIT OF CONTINUING OPERATIONS IN RANGE OF EUR 10 TO 12 MILLION.ADJUSTED EBIT WOULD BE APPROXIMATELY EUR 70 TO 80 MILLION IN 2018.  Full Article

Biotest: Phase IIa Study Demonstrates Favorable Safety And Tolerability Profile Monoclonal Antibody Bt-063
Thursday, 19 Jul 2018 

July 19 (Reuters) - BIOTEST AG ::PHASE IIA STUDY DEMONSTRATES FAVORABLE SAFETY AND TOLERABILITY PROFILE FOR BIOTEST'S MONOCLONAL ANTIBODY BT-063 FOR TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS (SLE).  Full Article

Biotest: All Conditions Met For Creat Takeover Of Biotest
Friday, 19 Jan 2018 

Jan 19 (Reuters) - BIOTEST AG ::DGAP-ADHOC: BIOTEST AG: ALL CONDITIONS MET FOR CREAT TAKEOVER OF BIOTEST.FOREIGN TRADE APPROVAL HAS BEEN GIVEN BY U.S. COMMITTEE ON FOREIGN INVESTMENT IN UNITED STATES (CFIUS).LAST REMAINING CONDITION HAS BEEN MET FOR TAKEOVER OFFER BY TIANCHENG (GERMANY) PHARMACEUTICAL HOLDINGS AG.THUS UNSOLICITED TAKEOVER BID ANNOUNCED ON MAY 18, 2017 FOR SHARES OF BIOTEST AG BECOMES EFFECTIVE.IN CONNECTION WITH APPROVAL, BIOTEST HAS SIGNED AN AGREEMENT FOR SALE OF ITS U.S. COMPANIES.  Full Article

Biotest 9-mth revenue at EUR 377.8 mln
Tuesday, 14 Nov 2017 

Nov 14 (Reuters) - BIOTEST AG ::DGAP-NEWS: BIOTEST AG: BIOTEST GENERATES REVENUES OF EUR 377.8 MILLION IN THE FIRST NINE MONTHS 2017.9M REVENUE 377.8 MILLION EUR.‍PAUL-EHRLICH INSTITUTE APPROVES PHASE III TRIAL IN INDICATION OF ACQUIRED FIBRINOGEN DEFICIENCY​.‍EBIT OF CONTINUING OPERATIONS TOTALED EUR -15.7 MILLION IN FIRST THREE QUARTERS OF 2017 AFTER EUR 47.5 MILLION​.9-MONTH ‍EARNINGS AFTER TAXES OF CONTINUING OPERATIONS OF EUR -22.7 MILLION VERSUS EUR 13.3 MILLION YEAR AGO​.  Full Article

Biotest: Tiancheng withdrawal of application of transaction from CFIUS and refiling
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - BIOTEST AG ::‍TENDER OFFER BY TIANCHENG (GERMANY) PHARMACEUTICAL HOLDINGS AG​.‍TIANCHENG WITHDRAWAL OF APPLICATION OF TRANSACTION FROM CFIUS AND REFILING​.BIOTEST - ‍TIANCHENG AND BIOTEST TO WITHDRAW THEIR NOTICE AND TO REFILE NEW APPLICATION WITH REQUEST FOR EXPEDITED REVIEW PERIOD​.  Full Article

German stocks - Factors to watch on Nov. 14

BERLIN, Nov 14 The following are some of the factors that may move German stocks on Wednesday: